Shamburg News · 8-K filed Nov 3, 2026, 9:15 AM EST

Impact Biomedical and Zoar Limited Announce SEC Effectiveness of Form F-4 for Business Combination

IBO · IMPACT BIOMEDICAL INC.

  • Other event
  • Shareholder vote
  • Material agreement
  • Materiality: medium

Impact Biomedical Inc. and Zoar Limited announced that the SEC declared effective on October 23, 2026, the Form F-4 registration statement for the proposed Business Combination involving Impact, Zoar Limited and Zoar Labs Limited. Impact's special meeting of stockholders to vote on the Business Combination is scheduled for November 13, 2026, at 10:00 a.m. Eastern Standard Time. Completion remains subject to stockholder approval, NYSE American listing approval for PubCo shares, and other closing conditions.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Items 7.01, 9.01, accession 0001493152-26-049727.

Written from the filing by Shamburg Markets. Figures are as reported by the company.